MarketCap
Facebook
X
TelegramQuarterly report 2024-Q2
added 08-07-2024
Alimera Sciences Depreciation & Amortization 2011-2026 | ALIM
Annual Depreciation & Amortization Alimera Sciences
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 8.75 M | 2.71 M | 2.58 M | 2.68 M | 2.64 M | 2.64 M | 2.68 M | 2.77 M | 2.56 M | 659 K | 138 K | 106 K | 133 K |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 8.75 M | 106 K | 2.39 M |
Quarterly Depreciation & Amortization Alimera Sciences
| 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3.09 M | 3.08 M | - | 1.87 M | 681 K | - | 2.02 M | 670 K | 689 K | - | 1.92 M | 633 K | 638 K | - | 2.02 M | 1.34 M | 654 K | - | 1.97 M | 1.31 M | 652 K | - | 1.94 M | 1.3 M | 649 K | - | 2.01 M | 1.33 M | 666 K | - | 2.08 M | 1.38 M | 689 K | - | 1.86 M | 1.21 M | 558 K | - | 151 K | 69 K | 36 K | - | 101 K | 59 K | 27 K | - | 80 K | 53 K | 26 K | - | 106 K | 79 K | 44 K |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 3.09 M | 26 K | 994 K |
Depreciation & Amortization of other stocks in the Drug manufacturers industry
| Issuer | Depreciation & Amortization | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AcelRx Pharmaceuticals
ACRX
|
311 K | - | 7.5 % | $ 6.35 M |  USA |
 |
Agile Therapeutics
AGRX
|
102 K | - | 10.11 % | $ 58.2 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
1.48 M | - | 0.86 % | $ 117 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
6.4 M | - | - | $ 754 M | USA |
 |
Catalent
CTLT
|
489 M | - | - | $ 11.5 B | USA |
 |
Eagle Pharmaceuticals
EGRX
|
646 K | - | -39.89 % | $ 27.7 M | USA |
 |
Endo International plc
ENDP
|
306 M | - | - | $ 28.9 M |  Irlanda |
 |
DURECT Corporation
DRRX
|
31 K | - | - | $ 50.1 M | USA |
 |
Athenex
ATNX
|
4.47 M | - | -23.39 % | $ 1.76 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
2.68 M | - | - | $ 2.06 B |  France |
 |
Cumberland Pharmaceuticals
CPIX
|
4.9 M | $ 3.05 | -2.24 % | $ 42.9 M | USA |
 |
Bausch Health Companies
BHC
|
1.26 B | $ 5.71 | -0.26 % | $ 2.08 B |  Canada |
 |
Tilray
TLRY
|
35.7 M | $ 6.89 | 2.53 % | $ 4.26 B | Canada |
 |
Harrow Health
HROW
|
1.32 M | $ 37.97 | 2.35 % | $ 1.4 B | USA |
 |
Canopy Growth Corporation
CGC
|
21.5 M | $ 1.09 | 0.46 % | $ 117 M | Canada |
 |
Veru
VERU
|
268 K | $ 2.39 | 0.42 % | $ 322 M | USA |
 |
Jupiter Wellness
JUPW
|
654 K | - | - | $ 33.6 M | USA |
 |
Lannett Company
LCI
|
34.3 M | - | 1.15 % | $ 7.11 M | USA |
 |
Viatris
VTRS
|
2.74 B | $ 13.97 | 0.98 % | $ 16.8 B | USA |
 |
Neoleukin Therapeutics
NLTX
|
3.04 M | - | - | $ 193 M | Canada |
 |
Evolus
EOLS
|
7.51 M | $ 4.39 | 1.5 % | $ 283 M | USA |
 |
Emergent BioSolutions
EBS
|
125 M | $ 8.53 | 3.52 % | $ 437 M | USA |
 |
Organogenesis Holdings
ORGO
|
13.6 M | $ 2.47 | 3.57 % | $ 325 M | USA |
 |
Pacira BioSciences
PCRX
|
78.8 M | $ 23.72 | -1.41 % | $ 1.1 B | USA |
 |
PetIQ
PETQ
|
44.5 M | - | 1.64 % | $ 400 M | USA |
 |
ProPhase Labs
PRPH
|
4.72 M | - | - | $ 5.07 M | USA |
 |
Relmada Therapeutics
RLMD
|
1.26 K | $ 7.24 | -1.9 % | $ 286 M | USA |
 |
Assertio Holdings
ASRT
|
30 M | $ 18.02 | 0.03 % | $ 115 M | USA |
 |
Radius Health
RDUS
|
1.16 M | - | - | $ 1.42 B | USA |
 |
Recro Pharma
REPH
|
8.22 M | - | -4.76 % | $ 65.3 M | USA |
 |
cbdMD
YCBD
|
452 K | $ 0.73 | -2.42 % | $ 3.15 M | USA |
 |
OptiNose
OPTN
|
402 K | - | - | $ 1.08 B | USA |
 |
SCYNEXIS
SCYX
|
580 K | $ 1.03 | 1.98 % | $ 51.4 M | USA |
 |
PLx Pharma
PLXP
|
116 K | - | -27.8 % | $ 2.56 M | USA |
 |
Solid Biosciences
SLDB
|
1.64 M | $ 8.24 | -1.73 % | $ 721 M | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
138 K | $ 2.17 | -7.66 % | $ 2.69 M | USA |
 |
Zomedica Corp.
ZOM
|
2.06 M | - | -0.21 % | $ 98 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
219 K | - | - | $ 55.5 M | USA |
 |
Rockwell Medical
RMTI
|
2.19 M | $ 0.91 | -2.76 % | $ 32.7 M | USA |
 |
Tricida
TCDA
|
442 K | - | - | $ 3.25 M | USA |
 |
China Pharma Holdings
CPHI
|
1.5 M | $ 0.63 | -3.05 % | $ 2.7 M |  China |
 |
TherapeuticsMD
TXMD
|
384 K | $ 2.15 | 4.63 % | $ 24.9 M | USA |